Literature DB >> 1260680

Treatment of Bowen's disease with topical dinitrochlorobenzene and 5-fluorouracil.

J H Raaf, S E Krown, C M Pinsky, W Cunningham-Rundles, B Safai, H F Oettgen.   

Abstract

"Bowen's disease" is a clinical and histologic diagnosis describing the lesions (single or multiple) of cutaneous in situ squamous cell carcinoma. The case of a 54-year-old man with 60 such intra-epidermal carcinomas, and a history of arsenic ingestion, is presented. The patient was sensitized to dinitrochlorobenzene (DNCB), and his lesions were treated with a topical DNCB preparation. All lesions disappeared completely (demonstrated by biopsy of several sites) except for a large (12 X 7 cm) tumor on the flank which partially resolved. Total regression of this lesion was achieved by adding topical 5-fluorouracil (5-FU) therapy. This case demonstrates that the inflammatory reaction induced by DNCB (as evidenced by erythema and by a dense inflammatory cell infiltrate in biopsied areas of treated lesions) can lead to regression of extensive in situ epidermoid carcinoma, and that combined therapy with DNCB and 5-FU can be more effective than DNCB alone. Both agents in appropriate concentrations led to selective destruction of neoplastic tissue with no effect on adjacent normal skin. No systemic toxicity was observed.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1260680     DOI: 10.1002/1097-0142(197604)37:4<1633::aid-cncr2820370403>3.0.co;2-p

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  3 in total

1.  Prophylaxis of FANFT induced bladder tumours in rats by intravesical DNCB instillation.

Authors:  D K Johnson; J E Pontes; R Izbicki; J M Pierce
Journal:  Urol Res       Date:  1980

Review 2.  Use of Contact Immunotherapy in the Treatment of Skin Diseases Other than Alopecia Areata.

Authors:  Kun-Wei Lai; Tsen-Fang Tsai
Journal:  Dermatol Ther (Heidelb)       Date:  2022-09-22

3.  Bowen's disease - a review of newer treatment options.

Authors:  Thorsten Neubert; Percy Lehmann
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.